GURUFOCUS.COM » STOCK LIST » USA » NYSE » Biohaven Ltd (NYSE:BHVN) » Definitions » Loans Receivable
Switch to:

Biohaven (NYSE:BHVN) Loans Receivable

: $0.00 Mil (As of Sep. 2022)
View and export this data going back to 2022. Start your Free Trial

Biohaven's Loans Receivable for the quarter that ended in Sep. 2022 was $0.00 Mil.


Biohaven Loans Receivable Historical Data

The historical data trend for Biohaven's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Annual Data
Trend Dec20 Dec21
Loans Receivable
- -

Biohaven Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22
Loans Receivable Premium Member Only - - - - -

Biohaven Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Biohaven Loans Receivable Related Terms

Thank you for viewing the detailed overview of Biohaven's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven (NYSE:BHVN) Business Description

Biohaven logo
Comparable Companies
Traded in Other Exchanges
N/A
Address
215 Church Street, New Haven, CT, USA, 06510
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Its neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. Its products target diseases such as migraine, depression, bipolar, and schizophrenia.
Executives
George C. Clark officer: VP, Chief Accounting Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Gregory Bailey director 4 A CHESHAM STREET, LONDON X0 SW1X8DT
Kimberly Gentile officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John W Childs director 111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Vlad Coric director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Irina Antonijevic director 215 CHURCH STREET, NEW HAVEN CT 06510
Matthew Buten officer: Chief Financial Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Kishan Mehta director 540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd. 10 percent owner 215 CHURCH STREET, NEW HAVEN CT 06510
Bruce Car officer: Chief Scientific Officer AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139

Biohaven (NYSE:BHVN) Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership